This page provides study documentation for BA15. For description of the specimen results, see Specimen Results Description (open to public). When available, dData sets of the specimen results are included in the existing WHI datasets located on the WHI Data on this site (sign in and a completed Data Distribution Agreement are required; see details on the Data site).
Investigator Names and Contact Information
Marty McIntosh, PhD, email@example.com
Ovarian Cancer (OC) is the fourth leading cause of cancer death of women in the United States. Our goal is to develop strategies to detect it in an earlier more treatable stage. We propose to use state-of-the-art proteomics technologies and novel computational strategies to identify plasma proteins that can detect the majority of women with Serous Ovarian Cancer (SOC), the most common and most deadly subtype of OC, three years or more before it presents clinically. The rationale for our goal follows from several factors, including the evidence that some proteins in the blood of SOC patients elevate three or more years before clinical diagnosis, and that our proteomic technologies are capable of identifying and measuring blood protein changes following OC development. Together these factors suggest that blood-based discovery of biomarkers for OC is feasible with the technologies and methodologies at our disposal.